<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEREZYME- imiglucerase injection, powder, lyophilized, for solution </strong><br>Genzyme Corporation<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e2d979ba-61a0-4909-a8a3-865cb86cf8d9"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Cerezyme<span class="Sup">®</span><br>(imiglucerase for injection)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="f0ad16fc-fec3-412d-8921-7387ba7f7e8b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> (imiglucerase for injection) is an analogue of the human
                            enzyme β-glucocerebrosidase, produced by recombinant DNA
                            technology. β-Glucocerebrosidase
                            (β-D-glucosyl-N-acylsphingosine glucohydrolase, E.C. 3.2.1.45)
                            is a lysosomal glycoprotein enzyme which catalyzes the hydrolysis of the
                            glycolipid glucocerebroside to glucose and ceramide. </p>
<p><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> is produced by recombinant DNA technology using mammalian
                            cell culture (Chinese hamster ovary). Purified imiglucerase is a
                            monomeric glycoprotein of 497 amino acids, containing 4 N-linked
                            glycosylation sites (Mr = 60,430). Imiglucerase differs from placental
                            glucocerebrosidase by one amino acid at position 495, where histidine is
                            substituted for arginine. The oligosaccharide chains at the
                            glycosylation sites have been modified to terminate in mannose sugars.
                            The modified carbohydrate structures on imiglucerase are somewhat
                            different from those on placental glucocerebrosidase. These
                            mannose-terminated oligosaccharide chains of imiglucerase are
                            specifically recognized by endocytic carbohydrate receptors on
                            macrophages, the cells that accumulate lipid in Gaucher disease. </p>
<p><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> is supplied as a sterile, non-pyrogenic, white to off-white
                            lyophilized product. The quantitative composition of the lyophilized
                            drug is provided in the following table: </p>
<a name="Tde6a92c7-4396-4d99-b3d6-d79d498615e3"></a><table>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left">Ingredient</th>
<th class="Botrule Lrule Rrule Toprule" align="center">200
                                        Unit Vial</th>
<th class="Botrule Lrule Rrule Toprule" align="center">400
                                        Unit Vial</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>
                                               This provides a respective
                                            withdrawal dose of 200 and 400 units of imiglucerase.
                                        </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">Imiglucerase (total amount)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">212
                                        units</td>
<td class="Botrule Lrule Rrule Toprule" align="center">424
                                        units</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Mannitol</td>
<td class="Botrule Lrule Rrule Toprule" align="center">170
                                        mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">340
                                        mg</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Sodium
                                        Citrates<br>    (Trisodium
                                        Citrate)<br>    (Disodium
                                        Hydrogen Citrate)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">70
                                        mg<br>(52 mg)<br>(18 mg)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">140
                                        mg<br>(104 mg)<br>(36 mg)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Polysorbate 80, NF</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.53
                                        mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.06
                                        mg</td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3">Citric Acid and/or Sodium Hydroxide may have
                                        been added at the time of manufacture to adjust pH.</td></tr>
</tbody>
</table>
<p>An enzyme unit (U) is defined as the amount of enzyme that
                            catalyzes the hydrolysis of 1 micromole of the synthetic substrate
                            para-nitrophenyl-β-D-glucopyranoside (pNP-Glc) per minute at
                            37°C. The product is stored at 2-8°C
                            (36-46°F). After reconstitution with Sterile Water for
                            Injection, USP, the imiglucerase concentration is 40 U/mL (see <span class="Bold"><span class="Emphasis"><a href="#e12c3788-eb0b-4227-b4ac-9435a25714a9"> DOSAGE
                                        AND ADMINISTRATION</a></span></span> for final concentrations and volumes). Reconstituted
                            solutions have a pH of approximately 6.1.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f28aaf95-a17f-4036-95f2-b8982b989502"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="eb7b6031-781d-4764-9545-9da781037812"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action/Pharmacodynamics</h2>
<p class="First">Gaucher disease is characterized by a deficiency of
                                    β-glucocerebrosidase activity, resulting in
                                    accumulation of glucocerebroside in tissue macrophages which
                                    become engorged and are typically found in the liver, spleen,
                                    and bone marrow and occasionally in lung, kidney, and intestine.
                                    Secondary hematologic sequelae include severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and
                                    <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in addition to the characteristic progressive
                                    <span class="product-label-link" type="condition" conceptid="4279681" conceptname="Hepatosplenomegaly">hepatosplenomegaly</span>, skeletal complications, including
                                    <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span> and <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span> with secondary pathological
                                    <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection) catalyzes the hydrolysis
                                    of glucocerebroside to glucose and ceramide. In clinical trials,
                                        <span class="Bold"><span class="Emphasis">Cerezyme</span></span> improved <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, reduced spleen
                                    and liver size, and decreased <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> to a degree similar to
                                    that observed with Ceredase® (alglucerase
                                injection).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ccefcd25-4fa8-491f-a448-5db7e81090e7"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">During one-hour intravenous infusions of four doses (7.5,
                                    15, 30, 60 U/kg) of <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection), steady-state enzymatic
                                    activity was achieved by 30 minutes. Following infusion, plasma
                                    enzymatic activity declined rapidly with a half-life ranging
                                    from 3.6 to 10.4 minutes. Plasma clearance ranged from 9.8 to
                                    20.3 mL/min/kg (mean ± S.D., 14.5 ± 4.0
                                    mL/min/kg). The volume of distribution corrected for weight
                                    ranged from 0.09 to 0.15 L/kg (0.12 ± 0.02 L/kg). These
                                    variables do not appear to be influenced by dose or duration of
                                    infusion. However, only one or two patients were studied at each
                                    dose level and infusion rate. The pharmacokinetics of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> do not appear to be different from placental-derived
                                    alglucerase (Ceredase®).</p>
<p>In patients who developed IgG antibody to <span class="Bold"><span class="Emphasis">Cerezyme</span></span>, an apparent effect on serum enzyme levels resulted
                                    in diminished volume of distribution and clearance and increased
                                    elimination half-life compared to patients without antibody (see
                                        <span class="Bold"><span class="Emphasis"><a href="#c9e16ad0-ea56-490a-b7cc-0f73c34a3da9">
                                                WARNINGS</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ec13afe4-bd04-4640-8614-0908127be742"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Cerezyme® </span></span>(imiglucerase for injection) is indicated for long-term enzyme
                            replacement therapy for pediatric and adult patients with a confirmed
                            diagnosis of Type 1 Gaucher disease that results in one or more of the
                            following conditions:</p>
<p>a. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span><br>b. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span><br>c. bone disease<br>d.
                            <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> or <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="eb849a2b-dc99-45d2-9b76-7441f4f50f3f"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">There are no known contraindications to the use of <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection). Treatment with <span class="Bold"><span class="Emphasis">Cerezyme</span></span> should be carefully re-evaluated if there is significant
                            clinical evidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="c9e16ad0-ea56-490a-b7cc-0f73c34a3da9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Approximately 15% of patients treated and tested to date
                            have developed IgG antibody to <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection) during the first year of
                            therapy. Patients who developed IgG antibody did so largely within 6
                            months of treatment and rarely developed antibodies to <span class="Bold"><span class="Emphasis">Cerezyme</span></span> after 12 months of therapy. Approximately 46% of
                            patients with detectable IgG antibodies experienced symptoms of
                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. </p>
<p>Patients with antibody to <span class="Bold"><span class="Emphasis">Cerezyme</span></span> have a higher risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Conversely,
                            not all patients with symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have detectable IgG
                            antibody. It is suggested that patients be monitored periodically for
                            IgG antibody formation during the first year of treatment.</p>
<p>Treatment with <span class="Bold"><span class="Emphasis">Cerezyme</span></span> should be approached with caution in patients who have
                            exhibited symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product.</p>
<p><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span> has been reported in less than 1%
                            of the patient population. Further treatment with imiglucerase should be
                            conducted with caution. Most patients have successfully continued
                            therapy after a reduction in rate of infusion and pretreatment with
                            antihistamines and/or corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f604f174-8457-4729-916e-ffb8c43fa995"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="cd953144-fbda-4b16-a130-2d95f47d3afe"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">In less than 1% of the patient population,
                                    <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> have also been observed
                                    during treatment with <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection). <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span>
                                    and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> are known complications of Gaucher disease and
                                    have been observed both in patients receiving and not receiving
                                        <span class="Bold"><span class="Emphasis">Cerezyme</span></span>. No causal relationship with <span class="Bold"><span class="Emphasis">Cerezyme</span></span> has been established. Patients with respiratory
                                    symptoms in the absence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> should be evaluated for the
                                    presence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.</p>
<p>Therapy with <span class="Bold"><span class="Emphasis">Cerezyme</span></span> should be directed by physicians knowledgeable in the
                                    management of patients with Gaucher disease.</p>
<p>Caution may be advisable in administration of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> to patients previously treated with
                                    Ceredase® (alglucerase injection) and who have
                                    developed antibody to Ceredase® or who have exhibited
                                    symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Ceredase®.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="a8ab344e-7c7a-447d-ae0a-9c8d48f88ae2"></a><a name="section-7.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies have not been conducted in either animals or
                                    humans to assess the potential effects of <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection) on carcinogenesis,
                                    mutagenesis, or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="cec76926-a41c-41b5-8e5c-600a6fd8bad1"></a><a name="section-7.3"></a><p></p>
<h2>Teratogenic Effects: Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with
                                        <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection). It is also not known
                                    whether <span class="Bold"><span class="Emphasis">Cerezyme</span></span> can cause fetal harm when administered to a pregnant
                                    woman or can affect reproductive capacity. <span class="Bold"><span class="Emphasis">Cerezyme</span></span> should not be administered during pregnancy except
                                    when the indication and need are clear and the potential benefit
                                    is judged by the physician to substantially justify the
                                risk.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="a5385225-3e1b-4b28-955a-6f77d661e38b"></a><a name="section-7.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk, caution
                                    should be exercised when <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection) is administered to a
                                    nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="cd946dcc-65db-4252-82be-e0f335abc982"></a><a name="section-7.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection) have been established in
                                    patients between 2 and 16 years of age. Use of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> in this age group is supported by evidence from
                                    adequate and well-controlled studies of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> and Ceredase® (alglucerase injection) in
                                    adults and pediatric patients, with additional data obtained
                                    from the medical literature and from long-term postmarketing
                                    experience. <span class="Bold"><span class="Emphasis">Cerezyme</span></span> has been administered to patients younger than 2
                                    years of age, however the safety and effectiveness in patients
                                    younger than 2 have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ae508272-d9d6-4731-9243-809f5fc997ed"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Since the approval of <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> (imiglucerase for injection) in May 1994, Genzyme has
                            maintained a worldwide post-marketing database of spontaneously reported
                            adverse events and adverse events discussed in the medical literature.
                            The percentage of events for each reported adverse reaction term has
                            been calculated using the number of patients from these sources as the
                            denominator for total patient exposure to <span class="Bold"><span class="Emphasis">Cerezyme</span></span> since 1994. Actual patient exposure is difficult to obtain
                            due to the voluntary nature of the database and the continuous accrual
                            and loss of patients over that span of time. The actual number of
                            patients exposed to <span class="Bold"><span class="Emphasis">Cerezyme</span></span> since 1994 is likely to be greater than estimated from these
                            voluntary sources and, therefore, the percentages calculated for the
                            frequencies of adverse reactions are most likely greater than the actual
                            incidences.</p>
<p>Experience in patients treated with <span class="Bold"><span class="Emphasis">Cerezyme®</span></span> has revealed that approximately 13.8% of patients
                            experienced adverse events which were judged to be related to <span class="Bold"><span class="Emphasis">Cerezyme</span></span> administration and which occurred with an increase in
                            frequency. Some of the adverse events were related to the route of
                            administration. These include <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or
                            sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> at the site of venipuncture. Each of these events was
                            found to occur in &lt; 1% of the total patient population. </p>
<p>Symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been noted in
                            approximately 6.6% of patients. Onset of such symptoms has
                            occurred during or shortly after infusions; these symptoms include
                            <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>,
                            <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span> has also
                            been reported (see <span class="Bold"><span class="Emphasis"><a href="#c9e16ad0-ea56-490a-b7cc-0f73c34a3da9">
                                    WARNINGS</a></span></span>). Each of these events was found to occur in &lt;
                            1.5% of the total patient population. Pre-treatment with
                            antihistamines and/or corticosteroids and reduced rate of infusion have
                            allowed continued use of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> in most patients. </p>
<p>Additional adverse reactions that have been reported in
                            approximately 6.5% of patients treated with <span class="Bold"><span class="Emphasis">Cerezyme</span></span> include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,
                            <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.
                            Each of these events was found to occur in &lt; 1.5% of the
                            total patient population. </p>
<p>Incidence rates cannot be calculated from the spontaneously
                            reported adverse events in the post-marketing database. From this
                            database, the most commonly reported adverse events in children (defined
                            as ages 2 – 12 years) included <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,
                            <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, whereas in adolescents (&gt;12
                            – 16 years) and in adults (&gt;16 years) the most commonly
                            reported events included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, pruritis, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>In addition to the adverse reactions that have been observed in
                            patients treated with <span class="Bold"><span class="Emphasis">Cerezyme</span></span>, transient <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> has been reported for this
                            therapeutic class of drug.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="b879b608-52d2-4349-9231-2f426feed097"></a><a name="section-9"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span></h1>
<p class="First">Experience with doses up to 240 U/kg every 2 weeks have been
                            reported. At that dose there have been no reports of obvious
                        toxicity.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e12c3788-eb0b-4227-b4ac-9435a25714a9"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> (imiglucerase for injection) is administered by intravenous
                            infusion over 1-2 hours. Dosage should be individualized to each
                            patient. Initial dosages range from 2.5 U/kg of body weight 3 times a
                            week to 60 U/kg once every 2 weeks. 60 U/kg every 2 weeks is the dosage
                            for which the most data are available. Disease severity may dictate that
                            treatment be initiated at a relatively high dose or relatively frequent
                            administration. Dosage adjustments should be made on an individual basis
                            and may increase or decrease, based on achievement of therapeutic goals
                            as assessed by routine comprehensive evaluations of the
                            patient’s clinical manifestations.</p>
<p><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> should be stored at 2-8°C (36-46°F). After
                            reconstitution, <span class="Bold"><span class="Emphasis">Cerezyme</span></span> should be inspected visually before use. Because this is a
                            protein solution, slight flocculation (described as thin translucent
                            fibers) occurs occasionally after dilution. The diluted solution may be
                            filtered through an in-line low protein-binding 0.2 μm filter
                            during administration. Any vials exhibiting opaque particles or
                            discoloration should not be used. DO NOT USE <span class="Bold"><span class="Emphasis">Cerezyme</span></span> after the expiration date on the vial.</p>
<p>On the day of use, after the correct amount of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> to be administered to the patient has been determined, the
                            appropriate number of vials are each reconstituted with Sterile Water
                            for Injection, USP. The final concentrations and administration volumes
                            are provided in the following table:</p>
<table>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left"></th>
<th class="Botrule Lrule Rrule Toprule" align="center">200
                                        Unit Vial</th>
<th class="Botrule Lrule Rrule Toprule" align="center">400
                                        Unit Vial</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">Sterile
                                        water for reconstitution</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.1
                                        mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10.2
                                        mL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Final
                                        volume of reconstituted product</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.3
                                        mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10.6
                                        mL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Concentration after reconstitution</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40
                                        U/mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40
                                        U/mL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Withdrawal volume</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.0
                                        mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10.0
                                        mL</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Units
                                        of enzyme within final volume</td>
<td class="Botrule Lrule Rrule Toprule" align="center">200
                                        units</td>
<td class="Botrule Lrule Rrule Toprule" align="center">400
                                        units</td>
</tr>
</tbody>
</table>
<p>A nominal 5.0 mL for the 200 unit vial (10.0 mL for the 400 unit
                            vial) is withdrawn from each vial. The appropriate amount of <span class="Bold"><span class="Emphasis">Cerezyme</span></span> for each patient is diluted with 0.9% Sodium Chloride
                            Injection, USP, to a final volume of 100 – 200 mL. <span class="Bold"><span class="Emphasis">Cerezyme</span></span> is administered by intravenous infusion over 1-2 hours.
                            Aseptic techniques should be used when diluting the dose. Since <span class="Bold"><span class="Emphasis">Cerezyme</span></span> does not contain any preservative, after reconstitution,
                            vials should be promptly diluted and not stored for subsequent use.
                                <span class="Bold"><span class="Emphasis">Cerezyme</span></span>, after reconstitution, has been shown to be stable for up to
                            12 hours when stored at room temperature (25°C) and at
                            2-8°C. <span class="Bold"><span class="Emphasis">Cerezyme</span></span>, when diluted, has been shown to be stable for up to 24 hours
                            when stored at 2-8°C. </p>
<p>Relatively low toxicity, combined with the extended time course
                            of response, allows small dosage adjustments to be made occasionally to
                            avoid discarding partially used bottles. Thus, the dosage administered
                            in individual infusions may be slightly increased or decreased to
                            utilize fully each vial as long as the monthly administered dosage
                            remains substantially unaltered.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f650a7b1-4bd1-4dbb-90cc-0fd046889c16"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> (imiglucerase for injection) is supplied as a sterile,
                            non-pyrogenic, lyophilized product. It is available as follows:</p>
<p>    200 Units per Vial NDC
                            58468-1983-1<br>    400 Units per
                            Vial NDC 58468-4663-1</p>
<p>    Store at 2-8°C
                            (36-46°F).</p>
<p><span class="Bold"><span class="Emphasis"> Rx only </span></span></p>
<p><span class="Bold"><span class="Emphasis"> Cerezyme® </span></span> (imiglucerase for injection) is manufactured by:
                                <br><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">Genzyme Corporation </span></span><br><span class="Bold"><span class="Emphasis"> 500 Kendall Street </span></span><br><span class="Bold"><span class="Emphasis"> Cambridge, MA 02142
                                        USA</span></span></span></span></p>
<p>Certain manufacturing operations may have been performed by other
                        firms.</p>
<p>Cerezyme and Genzyme are registered trademarks of Genzyme Corporation.</p>
<p>6LE005D</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="a2585560-2c6d-47ec-88fe-fe7ed1a28bf9"></a><a name="section-12"></a><p></p>
<h1>Package Label - Principal Display Panel – 200 U</h1>
<p class="First">NDC 58468-1983-1 </p>
<p>Cerezyme<span class="Sup">®</span></p>
<p>imiglucerase for injection</p>
<p>200 Units</p>
<p>For Intravenous infusion only</p>
<p>genzyme<span class="Bold"><span class="Emphasis"> </span></span></p>
<p><img alt="Package Label - Principal Display Panel – 200 U" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=df60f030-866b-4374-a31f-8ae3f6b45c38&amp;name=cerezyme-figure-1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bbca9eb1-b173-477c-b2f1-ef912100baad"></a><a name="section-13"></a><p></p>
<h1>Package Label - Principal Display Panel – 400 U</h1>
<p class="First">NDC 58468-4663-1 </p>
<p>Cerezyme<span class="Sup">®</span></p>
<p>imiglucerase for injection</p>
<p>400 Units</p>
<p>For Intravenous infusion only</p>
<p>genzyme</p>
<p><img alt="Package Label - Principal Display Panel – 400 U" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=df60f030-866b-4374-a31f-8ae3f6b45c38&amp;name=cerezyme-figure-2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEREZYME 		
					</strong><br><span class="contentTableReg">imiglucerase injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58468-1983</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IMIGLUCERASE</strong> (IMIGLUCERASE) </td>
<td class="formItem">IMIGLUCERASE</td>
<td class="formItem">40 U  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">32.08 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">9.81 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DISODIUM HYDROGEN CITRATE</strong></td>
<td class="formItem">3.4 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58468-1983-1</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020367</td>
<td class="formItem">05/23/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEREZYME 		
					</strong><br><span class="contentTableReg">imiglucerase injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58468-4663</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IMIGLUCERASE</strong> (IMIGLUCERASE) </td>
<td class="formItem">IMIGLUCERASE</td>
<td class="formItem">40 U  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">32.08 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">9.81 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DISODIUM HYDROGEN CITRATE</strong></td>
<td class="formItem">3.4 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58468-4663-1</td>
<td class="formItem">10 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020367</td>
<td class="formItem">05/23/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genzyme Corporation
							(025322157)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Corporation</td>
<td class="formItem"></td>
<td class="formItem">926029653</td>
<td class="formItem">ANALYSIS(58468-4663), MANUFACTURE(58468-1983)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Limited</td>
<td class="formItem"></td>
<td class="formItem">229522842</td>
<td class="formItem">ANALYSIS(58468-4663)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Ireland Limited</td>
<td class="formItem"></td>
<td class="formItem">985127419</td>
<td class="formItem">MANUFACTURE(58468-4663)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Corporation</td>
<td class="formItem"></td>
<td class="formItem">050424395</td>
<td class="formItem">PACK(58468-1983), LABEL(58468-4663)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Corporation</td>
<td class="formItem"></td>
<td class="formItem">621224711</td>
<td class="formItem">ANALYSIS(58468-1983, 58468-4663)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c07ea20e-36bc-4f7b-a218-d79927f7c77e</div>
<div>Set id: df60f030-866b-4374-a31f-8ae3f6b45c38</div>
<div>Version: 7</div>
<div>Effective Time: 20121210</div>
</div>
</div> <div class="DistributorName">Genzyme Corporation</div></p>
</body></html>
